Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 28:2:891162.
doi: 10.3389/fepid.2022.891162. eCollection 2022.

A Comparison Between Omicron and Earlier COVID-19 Variants' Disease Severity in the Milan Area, Italy

David Consolazio  1   2 , Rossella Murtas  1 , Sara Tunesi  1 , Anna Lamberti  3 , Sabrina Senatore  3 , Marino Faccini  3 , Antonio Giampiero Russo  1
Affiliations

A Comparison Between Omicron and Earlier COVID-19 Variants' Disease Severity in the Milan Area, Italy

David Consolazio et al. Front Epidemiol. .

Abstract

Background: In the context of the fourth wave of the COVID-19 pandemic in Italy, which occurred in correspondence with the outbreak of the Omicron variant, it became fundamental to assess differences in the risk of severe disease between the Omicron variant and the earlier SARS-CoV-2 variants that were still in circulation despite Omicron becoming prevalent.

Methods: We collected data on 2,267 genotyped PCR-positive swab tests and assessed whether the presence of symptoms, risk of hospitalization, and recovery times were significantly different between Omicron and the earlier variants. Multivariable models adjusted for sex, age class, citizenship, comorbidities, and symptomatology allowed assessing the difference in outcomes between Omicron and the earlier variants according to vaccination status and timing of administration.

Results: Compared to the earlier variants in the same period, Omicron was less symptomatic, resulted in fewer hospital admissions for those who were unvaccinated and for those who were already immunized after the booster dose, and was associated with quicker recovery, yet not in subjects with three vaccination doses.

Conclusion: Despite being milder, Omicron's higher transmissibility and vaccine resistance should not lead to underrating its damage potential, especially with regard to hospital and health service saturation.

Keywords: COVID-19; Omicron; SARS-CoV-2; hospitalization; negativization; symptoms; vaccination; variants.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Smoothed weekly trend of share of SARS-CoV-2 sequences that are Omicron variant in Italy and worldwide (Italy excluded). Source: our elaboration of GISAID data (https://www.gisaid.org/).
Figure 2
Figure 2
Forest plot of COVID-19-related symptoms in Omicron vs. other variants (ref.). Logistic regression models adjusted for sex, age class (18–39, 40–49, 50–59, 60–69, and 70+), citizenship (Italian, foreigner), number of comorbidities (0, 1+), and vaccination status (unvaccinated; one dose; two doses 7–179 dbpt*; 2 doses ≥ 180 dbpt*; 3 doses <7 dbpt*; 3 doses ≥ 7 dbpt*). *dbpt, days before positive test.
Figure 3
Figure 3
Average adjusted predictions (AAPs) of (A) hospitalization and (B) recovery time in Omicron vs. other variants by vaccination status (unvaccinated; one dose; two doses 7–179 dbpt*; 2 doses ≥ 180 dbpt*; 3 doses <7 dbpt*; 3 doses ≥ 7 dbpt*). Models were adjusted for sex, age class (18–39, 40–49, 50–59, 60–69, and 70+), citizenship (Italian, foreigner), number of comorbidities (0, 1+), and number of symptoms (0–9). *dbpt, days before positive test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Stefanelli P, Trentini F, Petrone D, Mammone A, Ambrosio L, Manica M, et al. . Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 - January 2022. medRXiv [Preprint]. (2022). 10.1101/2022.01.27.22269949 - DOI - PMC - PubMed
    1. Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. . GISAID's role in pandemic response. China CDC Weekly. (2021) 3:1049–51. 10.46234/ccdcw2021.255 - DOI - PMC - PubMed
    1. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. (2017) 1:33–46. 10.1002/gch2.1018 - DOI - PMC - PubMed
    1. Shu Y, McCauley J. GISAID: global initiative on sharing all influenza data – from vision to reality. Eurosurveillance. (2017) 22:30494. 10.2807/1560-7917.ES.2017.22.13.30494 - DOI - PMC - PubMed
    1. Christie B. COVID-19: early studies give hope Omicron is milder than other variants. BMJ. (2021) 375:n3144. 10.1136/bmj.n3144 - DOI - PubMed